Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist's Evolving Role

Overview:

Small cell lung cancer (SCLC) is a highly aggressive malignancy accounts for less than 20% of lung cancers but contributes disproportionately to lung cancer-related mortality. Prognosis is particularly poor for patients who develop extensive-stage SCLC. Recent regulatory approvals and practice-changing data are redefining the extensive-stage SCLC treatment landscape and raising new considerations for selecting therapy and optimally incorporating emerging agents into practice.

Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist's Evolving Role, held in conjunction with the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will feature a panel of radiation oncology and medical oncology specialists who will review recent developments and highlight practical strategies to incorporate systemic therapies and radiation therapy to optimize outcomes for patients with extensive-stage SCLC.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate emerging systemic therapies for extensive-stage SCLC across lines of treatment
• Apply evidence for the intracranial activity of emerging systemic agents to individualize treatment in extensive-stage SCLC
• Differentiate and co-manage treatment-related adverse events associated with novel therapies for extensive-stage SCLC

Target Audience:

This educational activity is directed toward radiation oncologists, medical oncologists, and the multidisciplinary team — including NPs/PAs, oncology nurses, and pharmacists — involved in the management of patients with extensive-stage small cell lung cancer (SCLC), including those with brain metastases.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.